NDAORALTABLET1 Generic Approved
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
2
Data completeness
5/8 — Partial
MICARDIS HCT (telmisartan and hydrochlorothiazide) by Boehringer Ingelheim is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICARDIS HCT is a fixed-dose combination tablet combining telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) for oral administration. It treats hypertension by blocking angiotensin II receptors and reducing fluid volume, lowering blood pressure through dual mechanisms. Approved in 2000, it remains a standard antihypertensive option in the ARB+diuretic class.
$0.947MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with modest Part D volume signals a mature, declining brand requiring defensive strategies and potential transition planning for commercial teams.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
Started Apr 2006
4,255 enrolled
Hypertension
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
Started Jun 2004
583 enrolled
Hypertension
Career Relevance
Working on MICARDIS HCT as it approaches LOE offers limited growth trajectory but valuable experience in defensive brand strategy, payer negotiations, and mature product optimization. Career advancement depends on contributing to managed decline and transition planning rather than driving growth.
Worked on MICARDIS HCT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.